CASI Pharmaceuticals, Inc.
CASIF
$0.10
$0.00-2.38%
OTC PK
| 12/31/2025 | 09/30/2025 | 03/31/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 31.37M | 31.37M | 28.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 31.37M | 31.37M | 28.54M |
| Cost of Revenue | -- | -- | 18.41M | 18.41M | 17.39M |
| Gross Profit | -- | -- | 12.96M | 12.96M | 11.15M |
| SG&A Expenses | -- | -- | 44.81M | 44.81M | 41.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -7.00K | -7.00K | -2.00K |
| Total Operating Expenses | -- | -- | 71.59M | 71.59M | 67.75M |
| Operating Income | -- | -- | -40.23M | -40.23M | -39.21M |
| Income Before Tax | -- | -- | -40.48M | -40.48M | -39.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -40.48 | -40.48 | -39.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -40.48M | -40.48M | -39.26M |
| EBIT | -- | -- | -40.23M | -40.23M | -39.21M |
| EBITDA | -- | -- | -37.19M | -37.19M | -35.82M |
| EPS Basic | -- | -- | -2.51 | -2.51 | -2.53 |
| Normalized Basic EPS | -- | -- | -1.65 | -1.65 | -1.67 |
| EPS Diluted | -- | -- | -2.51 | -2.51 | -2.53 |
| Normalized Diluted EPS | -- | -- | -1.65 | -1.65 | -1.67 |
| Average Basic Shares Outstanding | -- | -- | 63.46M | 63.46M | 61.35M |
| Average Diluted Shares Outstanding | -- | -- | 63.46M | 63.46M | 61.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |